MEI Pharma, Kyowa Kirin to discontinue zandelisib development outside Japan

MEI Pharma and Kyowa Kirin Co. announced that after receiving the most recent guidance from a late November meeting with the U.S. FDA, the companies are discontinuing global development of zandelisib outside of Japan for B-cell malignancies. Kyowa Kirin is continuing the ongoing clinical trials including Phase 2 MIRAGE study evaluating Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphomas and will explore the potential for a submission to Japanese health authorities based on data from the MIRAGE and TIDAL clinical trials.